CHE analyst estimates
Chemed (CHE) analyst ratings, the average price target and its range, and every firm's latest call.
CHE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 28, 2026 | Jefferies | Jefferies Upgrades Chemed (CHE) to Buy | $620.00 |
| Sep 25, 2026 | UBS | Chemed initiated with a Buy at UBS | $650.00 |
| Jan 22, 2026 | Jefferies | Jefferies Downgrades Chemed (CHE) to Hold | $475.00 |
| Sep 2, 2025 | Jefferies | Chemed upgraded to Buy from Hold at Jefferies | $550.00 |
| Nov 5, 2024 | RBC Capital | Chemed (CHE) PT Lowered to $633 at RBC Capital | $633.00 |
| May 21, 2024 | RBC Capital | Chemed (CHE) PT Lowered to $697 at RBC Capital | $697.00 |
| Apr 28, 2022 | RBC Capital | RBC Capital Maintains Outperform on Chemed, Raises Price Target to $592 | $592.00 |
- 5 firms rate CHE: 3 buy, 2 hold, 0 sell.
- The average price target is $635.00 from 2 analysts, from $620.00 to $650.00.
Updated 2026-11-03 11:31 UTC